Shuttle Pharmaceuticals
SHPH
3 hedge funds and large institutions have $16.9K invested in Shuttle Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 4 closing their positions.
0.03% more ownership
Funds ownership: 0.01% → 0.04% (+0.03%)
40% less funds holding
Funds holding: 5 → 3 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
81% less capital invested
Capital invested by funds: $87.5K → $16.9K (-$70.6K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$20.2K |
| 2 |
Raymond James Financial
St Petersburg,
Florida
|
+$5.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$36.9K |
| 2 |
AC
Armistice Capital
New York
|
-$27.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$13.2K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$8.63K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$120 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $12.7K | +$20.2K | +337 | New |
|
|
2
Raymond James Financial
St Petersburg,
Florida
| $3.77K | +$5.98K | +100 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $463 | -$120 | -2 | -14% |
|
4
Bank of America
Charlotte,
North Carolina
| $11 | – | – | – |
|
|
FDCDDQ
5
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $8 | – | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$36.9K | -380 | Closed |
|
|
AC
7
Armistice Capital
New York
| – | -$27.4K | -282 | Closed |
|
|
8
Geode Capital Management
Boston,
Massachusetts
| – | -$13.2K | -136 | Closed |
|
|
TSS
9
Two Sigma Securities
New York
| – | -$8.63K | -89 | Closed |
|
10
Barclays
London,
United Kingdom
| – | -$1 | – | – |
|
SHPH Hedge Fund Activity: Q2 2025 in Review
3 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q2 2025, worth a combined $16.9K — down 81% from $87.5K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SHPH and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $20.2K. The largest seller was Citadel Advisors, exiting entirely with an estimated $36.9K sold.
- 3 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q2 2025, down from 5 in Q1 2025.
- Funds reported $16.9K of Shuttle Pharmaceuticals stock for Q2 2025, down 81% quarter-over-quarter.
- 2 funds opened new Shuttle Pharmaceuticals positions in Q2 2025 and 4 closed out, a net change of -2 holders.
- The largest Shuttle Pharmaceuticals buyer in Q2 2025 was UBS Group, an estimated $20.2K added.
- The largest Shuttle Pharmaceuticals seller in Q2 2025 was Citadel Advisors, an estimated $36.9K sold.
Based on aggregated 13F filings for Q2 2025.